Cargando…
The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study
Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft‐tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty‐two cases wer...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858130/ https://www.ncbi.nlm.nih.gov/pubmed/27499911 http://dx.doi.org/10.1002/cjp2.29 |
_version_ | 1782430758161350656 |
---|---|
author | Jour, George Wang, Lu Middha, Sumit Zehir, Ahmet Chen, Wen Sadowska, Justyna Healey, John Agaram, Narasimhan P Choi, Lisa Nafa, Khedoudja Hameed, Meera |
author_facet | Jour, George Wang, Lu Middha, Sumit Zehir, Ahmet Chen, Wen Sadowska, Justyna Healey, John Agaram, Narasimhan P Choi, Lisa Nafa, Khedoudja Hameed, Meera |
author_sort | Jour, George |
collection | PubMed |
description | Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft‐tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty‐two cases were retrieved and histomorphology was reviewed. Clinical history and follow‐up were obtained through electronic record review. DNA from formalin‐fixed paraffin‐embedded (FFPE) tissue was extracted and processed from 27 cases. Genome‐wide DNA copy number (CN) alterations and allelic imbalances were analyzed by single nucleotide polymorphism array using Affymetrix OncoScan FFPE Assay. Massive high‐throughput deep parallel sequencing was performed using a customized panel targeting 410 cancer genes. Log rank, Fisher's exact test and Cox proportional hazards were used for statistical analysis. In this series of 32 patients (male n = 12, female n = 20), the average age was 66 years (19–93) and median follow up was 24 months (range 6–120 months). Frequent genomic alterations included CN losses in tumour suppressor genes including CDKN2A (70%), TP53 (56%) and RB1 (49%). Mutations affecting methylation/demethylation, chromatin remodeling and WNT/SHH pathways were identified in 40%, 27%, and 27%, respectively. PIK3CA and TERT promoter variant mutations were identified in 11% of the cases. Cases harbouring simultaneous TP53 and RB1 biallelic CN losses were associated with worse overall survival and local recurrence (p = 0.04, p = 0.02, respectively). CDKN2A losses and positive margins were also associated with worse overall survival (p = 0.002; p = 0.03, respectively). Our findings suggest that age above 60, positive margin status, simultaneous biallelic TP53 and RB1 losses and CDKN2A loss are associated with a worse outcome in ESOSA. Comparison between conventional paediatric osteosarcoma and ESOSA shows that, while both share genetic similarities, there are notable dissimilarities and mechanistic differences in the molecular pathways involved in ESOSA. |
format | Online Article Text |
id | pubmed-4858130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48581302016-08-05 The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study Jour, George Wang, Lu Middha, Sumit Zehir, Ahmet Chen, Wen Sadowska, Justyna Healey, John Agaram, Narasimhan P Choi, Lisa Nafa, Khedoudja Hameed, Meera J Pathol Clin Res Original Articles Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft‐tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty‐two cases were retrieved and histomorphology was reviewed. Clinical history and follow‐up were obtained through electronic record review. DNA from formalin‐fixed paraffin‐embedded (FFPE) tissue was extracted and processed from 27 cases. Genome‐wide DNA copy number (CN) alterations and allelic imbalances were analyzed by single nucleotide polymorphism array using Affymetrix OncoScan FFPE Assay. Massive high‐throughput deep parallel sequencing was performed using a customized panel targeting 410 cancer genes. Log rank, Fisher's exact test and Cox proportional hazards were used for statistical analysis. In this series of 32 patients (male n = 12, female n = 20), the average age was 66 years (19–93) and median follow up was 24 months (range 6–120 months). Frequent genomic alterations included CN losses in tumour suppressor genes including CDKN2A (70%), TP53 (56%) and RB1 (49%). Mutations affecting methylation/demethylation, chromatin remodeling and WNT/SHH pathways were identified in 40%, 27%, and 27%, respectively. PIK3CA and TERT promoter variant mutations were identified in 11% of the cases. Cases harbouring simultaneous TP53 and RB1 biallelic CN losses were associated with worse overall survival and local recurrence (p = 0.04, p = 0.02, respectively). CDKN2A losses and positive margins were also associated with worse overall survival (p = 0.002; p = 0.03, respectively). Our findings suggest that age above 60, positive margin status, simultaneous biallelic TP53 and RB1 losses and CDKN2A loss are associated with a worse outcome in ESOSA. Comparison between conventional paediatric osteosarcoma and ESOSA shows that, while both share genetic similarities, there are notable dissimilarities and mechanistic differences in the molecular pathways involved in ESOSA. John Wiley and Sons Inc. 2015-10-29 /pmc/articles/PMC4858130/ /pubmed/27499911 http://dx.doi.org/10.1002/cjp2.29 Text en © 2015 John Wiley and Sons Ltd and The Pathological Society of Great Britain and Ireland This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Jour, George Wang, Lu Middha, Sumit Zehir, Ahmet Chen, Wen Sadowska, Justyna Healey, John Agaram, Narasimhan P Choi, Lisa Nafa, Khedoudja Hameed, Meera The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study |
title | The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study |
title_full | The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study |
title_fullStr | The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study |
title_full_unstemmed | The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study |
title_short | The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study |
title_sort | molecular landscape of extraskeletal osteosarcoma: a clinicopathological and molecular biomarker study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858130/ https://www.ncbi.nlm.nih.gov/pubmed/27499911 http://dx.doi.org/10.1002/cjp2.29 |
work_keys_str_mv | AT jourgeorge themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT wanglu themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT middhasumit themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT zehirahmet themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT chenwen themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT sadowskajustyna themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT healeyjohn themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT agaramnarasimhanp themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT choilisa themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT nafakhedoudja themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT hameedmeera themolecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT jourgeorge molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT wanglu molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT middhasumit molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT zehirahmet molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT chenwen molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT sadowskajustyna molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT healeyjohn molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT agaramnarasimhanp molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT choilisa molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT nafakhedoudja molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy AT hameedmeera molecularlandscapeofextraskeletalosteosarcomaaclinicopathologicalandmolecularbiomarkerstudy |